• 1
    Papagiannouli F,Lohmann I. Shaping the niche: Lessons from the Drosophila testis and other model systems. Biotechnol J 2012; 7: 723736.
  • 2
    Schofield R. The relationship between the spleen colony-forming cell and the haematopoietic stem cell. Blood Cells 1978; 4: 725.
  • 3
    Krause DS,Scadden DT,Preffer FI. The hematopoietic stem cell niche—Home for friend and foe? Cytometry B Clin Cytom 2013; 84B: 720.
  • 4
    Lo Celso C,Fleming HE,Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, Cote D, Rowe DW, Lin CP, Scadden DT. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009; 457: 9296.
  • 5
    Fulzele K,Krause DS,Panaroni C, Saini V, Barry KJ, Liu X, Lotinun S, Baron R, Bonewald L, Feng JQ, et al. Myelopoiesis is regulated by osteocytes through Gsalpha-dependent signaling. Blood 2012,DOI: 10.1182/blood-2012-06-437160 (in press).
  • 6
    Goncharova V,Serobyan N,Iizuka S, Schraufstatter I, de Ridder A, Povaliy T, Wacker V, Itano N, Kimata K, Orlovskaja IA, et al. Hyaluronan expressed by the hematopoietic microenvironment is required for bone marrow hematopoiesis. J Biol Chem 2012; 287: 2541925433.
  • 7
    Park D,Spencer JA,Koh BI, Kobayashi T, Fujisaki J, Clemens TL, Lin CP, Kronenberg HM, Scadden DT. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 2012; 10: 259272.
  • 8
    Preffer F,Domkowski D. Advances in complex multiparameter flow cytometry technology: Applications for stem cell research. Cytometry B Clin Cytom 2009; 76B: 295314.
  • 9
    Krause DS,Van Etten RA. Right on target: Eradicating leukemic stem cells. Trends Mol Med 2007; 13: 470481.
  • 10
    Lane SW,Scadden DT,Gilliland DG. The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood 2009; 114: 11501157.
  • 11
    Krause DS,Lazarides K,von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12: 11751180.
  • 12
    Jin L,Hope KJ,Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 11671174.
  • 13
    Matsunaga T,Takemoto N,Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 11581165.
  • 14
    Nervi B,Ramirez P,Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 62066214.
  • 15
    Krause DS,Fulzele K,Catic A, Hurley M, Lezeau S, Attar EC, Wu JY, Lin HY-F, Divieti-Pajevic P, Hasserjian RP, et al. Differential regulation of myeloid leukemia by the bone marrow microenvironment. Blood 2012; 120: 1245a.